Legis Daily

Fair Accountability and Innovative Research Drug Pricing Act of 2019

USA116th CongressS-1391| Senate 
| Updated: 5/9/2019
Tammy Baldwin

Tammy Baldwin

Democratic Senator

Wisconsin

Cosponsors (7)
Mike Braun (Republican)Angus S. King (Independent)Kevin Cramer (Republican)Tina Smith (Democratic)Sherrod Brown (Democratic)John Hoeven (Republican)Lisa Murkowski (Republican)

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Fair Accountability and Innovative Research Drug Pricing Act of 2019 This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 9, 2019
Introduced in Senate
May 9, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 9, 2019
    Introduced in Senate


  • May 9, 2019
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health

Related Bills

  • HR 116-2296: More Efficient Tools to Realize Information for Consumers Act
  • S 116-1895: Lower Health Care Costs Act
Business recordsCivil actions and liabilityCongressional oversightConsumer affairsCorporate finance and managementGovernment information and archivesGovernment studies and investigationsHealth care costs and insuranceInflation and pricesManufacturingMarketing and advertisingMedical researchPrescription drugsResearch and development

Fair Accountability and Innovative Research Drug Pricing Act of 2019

USA116th CongressS-1391| Senate 
| Updated: 5/9/2019
Fair Accountability and Innovative Research Drug Pricing Act of 2019 This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 9, 2019
Introduced in Senate
May 9, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 9, 2019
    Introduced in Senate


  • May 9, 2019
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Tammy Baldwin

Tammy Baldwin

Democratic Senator

Wisconsin

Cosponsors (7)
Mike Braun (Republican)Angus S. King (Independent)Kevin Cramer (Republican)Tina Smith (Democratic)Sherrod Brown (Democratic)John Hoeven (Republican)Lisa Murkowski (Republican)

Health, Education, Labor, and Pensions Committee

Health

Related Bills

  • HR 116-2296: More Efficient Tools to Realize Information for Consumers Act
  • S 116-1895: Lower Health Care Costs Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsCivil actions and liabilityCongressional oversightConsumer affairsCorporate finance and managementGovernment information and archivesGovernment studies and investigationsHealth care costs and insuranceInflation and pricesManufacturingMarketing and advertisingMedical researchPrescription drugsResearch and development